CD79A and infection: The majority of infections were seen in ibrutinib patients, therefore the contribution of the ITK in promoting immune reconstitution after the first 6 months of therapy must be taken into consideration: increasing levels of IgA have been described after the first year of ibrutinib treatment,35 as well as ITK inhibition36 that leads to recovery of TCR repertoire diversity37 by T‐cell reset with improvement of immunologic synapsis, reduction of Th2 and PD1 expression and conversely, Th1 increase.